Multi-omics study identifies two genes that drive glioblastoma brain cancer risk
Researchers used advanced genetic analysis to find LGALS9 and SELL genes causally linked to aggressive brain tumors, revealing new treatment targets.
Summary
Scientists used a comprehensive multi-omics approach combining genetics, protein analysis, and immune profiling to identify two genes—LGALS9 and SELL—that causally increase glioblastoma risk. The study revealed specific mechanisms: LGALS9 works through immune T cells, while SELL acts via brain fluid metabolites. Lab experiments confirmed both genes promote tumor growth, and researchers identified existing drugs like meclofenamate that could target SELL, offering new therapeutic possibilities for this deadly brain cancer.
Detailed Summary
Glioblastoma is the most aggressive brain cancer, with patients surviving only 12-18 months despite treatment. This groundbreaking study represents the first comprehensive multi-omics investigation using advanced genetic methods to identify causal factors driving this deadly disease.
Researchers analyzed genetic, protein, and metabolic data from glioblastoma patients, employing Mendelian randomization—a powerful technique that uses genetic variants as natural experiments to establish causation rather than just correlation. They identified two genes, LGALS9 and SELL, that directly increase glioblastoma risk.
The team uncovered specific mechanisms for each gene. LGALS9 promotes tumor development by affecting CD3 proteins on regulatory T cells, which normally help control immune responses. SELL works through a different pathway, influencing metabolites in cerebrospinal fluid that bathes the brain. Laboratory experiments confirmed both genes enhance cancer cell growth, movement, and invasion.
Most importantly, the researchers identified existing drugs that could target these pathways. Drug screening revealed meclofenamate, an anti-inflammatory medication, shows promise against SELL. This finding could accelerate treatment development since the drug is already approved for other conditions.
This research provides the strongest evidence to date for specific genetic drivers of glioblastoma and offers concrete therapeutic targets. The multi-omics approach represents a new standard for cancer research, moving beyond observational studies to establish true causation and identify actionable treatment strategies.
Key Findings
- LGALS9 and SELL genes causally increase glioblastoma risk through distinct biological pathways
- LGALS9 works via immune T cells, mediating 7% of its tumor-promoting effect
- SELL acts through brain fluid metabolites, accounting for 16% of its cancer-driving impact
- Meclofenamate drug shows promise for targeting SELL in potential new treatments
- Lab experiments confirmed both genes enhance tumor cell growth and invasion
Methodology
Researchers used integrative multi-omics combining transcriptomics, proteomics, and Mendelian randomization with genetic variants as instrumental variables. Two-step MR analyses explored mediating effects through immune cells and metabolites, with validation using independent datasets and in vitro experiments.
Study Limitations
Summary based on abstract only, limiting detailed methodology assessment. While Mendelian randomization provides strong causal evidence, findings require validation in larger clinical cohorts and human trials before therapeutic application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.